In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes.
about
Human engineered heart tissue as a versatile tool in basic research and preclinical toxicologyCardiac applications for human pluripotent stem cellsTissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screeningComputer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesIdentification and purification of human induced pluripotent stem cell-derived atrial-like cardiomyocytes based on sarcolipin expressionClinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine.The adverse cardiac effects of Di(2-ethylhexyl)phthalate and Bisphenol ACardiomyocyte MEA data analysis (CardioMDA)--a novel field potential data analysis software for pluripotent stem cell derived cardiomyocytesEvaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytesModelling the long QT syndrome with induced pluripotent stem cellsIsoflurane preconditioning elicits competent endogenous mechanisms of protection from oxidative stress in cardiomyocytes derived from human embryonic stem cells2D and 3D self-assembling nanofiber hydrogels for cardiomyocyte culture.Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposureConcise review: reprogramming strategies for cardiovascular regenerative medicine: from induced pluripotent stem cells to direct reprogrammingiPCS Cell Modeling of Inherited Cardiac Arrhythmias.Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects.Present state and future perspectives of using pluripotent stem cells in toxicology researchDrug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicityErg channel is critical in controlling cell volume during cell cycle in embryonic stem cells.Transcriptome-guided functional analyses reveal novel biological properties and regulatory hierarchy of human embryonic stem cell-derived ventricular cardiomyocytes crucial for maturationPhysical developmental cues for the maturation of human pluripotent stem cell-derived cardiomyocytes.Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytesBiomaterial based cardiac tissue engineering and its applicationsModel for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell cultureHuman pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.Marked hyperglycemia attenuates anesthetic preconditioning in human-induced pluripotent stem cell-derived cardiomyocytes.Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytesA review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytesMechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cellsHuman Engineered Heart Tissue: Analysis of Contractile ForceCardiac tissue engineering using stem cells.Embryonic Stem Cells as a Model for Cardiac Development and Disease.Induced human pluripotent stem cells: promises and open questions.Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells.Two dimensional electrophysiological characterization of human pluripotent stem cell-derived cardiomyocyte system.Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytesThree-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells.
P2860
Q21134989-1D9D58F7-A76D-4446-B86D-5681C0E5EFB4Q24615347-6ACF2A38-5F04-4FEF-8CD3-48BC33994500Q26799470-B5019B33-733F-4EA8-A0BA-50559D51B69CQ26861453-99854469-070E-4D4E-9FBB-201BF063224FQ27320909-95CEF8F4-6824-43B1-A67A-3F886C971A1DQ27693850-374A758B-1825-4781-8B58-DCE9317D3E0FQ28396757-76C3A61A-19D6-4C42-8053-AE0EF1236217Q28533644-2C81A121-8CB0-4416-9BFB-FF3165D6ADA8Q28542837-530B2125-6D24-440F-9936-85CA290F3BACQ29620092-A1F9FD59-7BD0-431F-9482-5C317575D77FQ30496731-74187C3E-8F38-48FE-9E86-9D496FD482ADQ30537357-C695011D-F849-42DA-B1BE-318266F421E2Q30558954-494B3E92-64D5-496C-9475-B29409829117Q33900003-493ABDB5-968F-411C-AB2B-08605AAC20A7Q34143269-C7F46550-C030-457E-9FB9-C9B94A03255FQ34408109-6DE45D9B-84FC-41FE-AF39-F01AEC6F3C36Q34431713-B0D1AD25-3E7B-48A2-9BAA-2FA8D55D3A26Q34461530-4888445F-4097-4CF4-BEEA-AEDC09EB0952Q34520935-211AAA06-96F3-48DE-B525-08531F787798Q34631498-95B2E052-203C-44DA-AA90-A5AB4D6145E8Q34927241-ED232A97-281C-4498-8740-B05855108ABBQ35035613-41F31B38-E425-47B7-91B6-E6EFE0350C41Q35414785-93F5BBF6-FE02-444F-8F05-6E4DFB3671FFQ35708176-DBC97E85-654C-46EB-929A-4B96F4C1D0EDQ35731251-3132CDF1-91ED-4919-A368-A87F21633185Q35794574-D6C37484-CB04-4B65-B5B2-5AA489F5A259Q36279078-0392A0B8-CDFC-4F0C-852F-5E954472D3F2Q36283727-F3C6A2EB-376A-4F6E-8965-B9BCBAB41DD2Q36365384-52BEE104-2AF2-452E-BC23-09228C41C513Q36566235-EBA85548-E8DE-4A5D-ACBB-11F19ED0879EQ36632323-B24950C4-862D-4A80-883F-234C9BD7194EQ36675819-2A4FD76E-64C7-489B-9FEA-448F90A00370Q37094032-F5FA7814-024F-4515-BE9F-9CB07A9333E3Q37261443-73707A5D-1196-4A14-8F9F-0B5A512E8447Q37313292-CE51B3F6-D1FC-4E24-B15E-C813365A6F2EQ37532537-7EC752DA-94A3-46A8-A7A4-84FF00B139C0Q37542604-C3199DEC-A7BE-4B0F-A8C4-4CABABE22058Q37683821-D45F0703-E661-4BB3-ADAA-8AC8DC2B672CQ37692479-5F690684-28CA-4BEA-99FE-A0E66481DC11Q37711224-1A09AEAE-7092-4379-BA90-8CE4A1AC5959
P2860
In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@en
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@nl
type
label
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@en
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@nl
prefLabel
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@en
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@nl
P2093
P356
P1476
In vitro electrophysiological ...... m cell derived cardiomyocytes.
@en
P2093
Amira Gepstein
Ilanit Itzhaki
Irit Huber
Izhak Kehat
Jonathan Satin
Lior Gepstein
Oren Caspi
P304
P356
10.1089/SCD.2007.0280
P577
2009-01-01T00:00:00Z